Is Eisai Co., Ltd. (ESALF) a Buy, Sell, or Hold?
OTC : ESALF
Eisai Co., Ltd.
$26.18 USD
$0 (0.0%)
- Volume
- 1
- Average Volume
- 72
- Market Capitalization
- $7.39B
- P/E Ratio
- 32.54
- Dividend Yield
- 3.60%
- Price Target
- Year High
- $35.83
- Year Low
- $23.88
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.17
- Current Ratio
- $2.24
Company Overview
OTC
Haruo Naito
Drug Manufacturers - Specialty & Generic
Healthcare
ESALF
10543
JP
USD
Liquidity Metrics
0.21
2.24
1.48
0.72
1.17
Sales & Valuation
$830.57B
1.52
1.40
27.31
163.06
Profitability
$137.41
$38.8B
4.67%
6.18%
4.44%
2.66%
P/E Metrics
32.54
-1.97
-1.97
Analyst Price Target & Rating
3/5
0 Analysts
%
Poll Results
About Eisai Co., Ltd. (OTC:ESALF) Stock
Eisai Co., Ltd., a pharmaceutical company headquartered in Tokyo, Japan, develops and markets a wide array of medicinal products. Its offerings for neurological conditions include Aricept, prescribed for Alzheimer's disease and dementia with Lewy bodies; Methycobal, used to treat peripheral neuropathy; Fycompa, an antiepileptic drug that serves as an adjunctive therapy for specific partial-onset and primary generalized tonic-clonic seizures; Lyrica, for various pain management needs; and Dayvigo, an anti-insomnia medication for adults. In the oncology field, Eisai provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (when used in combination with everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, a microtubule d ... ynamics inhibitor for breast cancer and liposarcoma. The company's portfolio also features Pariet, a proton-pump inhibitor effective in treating gastric and duodenal ulcers, reflux esophagitis, and for the eradication of Helicobacter pylori infections. Additionally, Eisai markets Humira, a fully human anti-TNF-alpha monoclonal antibody employed in managing autoimmune diseases such as rheumatoid arthritis. Beyond prescription medicines, Eisai provides consumer health products like Chocola BB Plus, a vitamin B2 preparation addressing rough skin and stomatitis, alongside various third-class over-the-counter (OTC) drugs, designated quasi-drugs, and functional foods. The company was established in 1941, initially operating as Nihon Eisai Co., Ltd., before adopting its current name, Eisai Co., Ltd., in 1955.
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
2026-07-13 15:02:12
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
2026-05-25 10:47:04
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
BioArctic Interim Report for the period January - March 2026
2026-05-20 03:30:00
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China New long-term and real-world data for Leqembi, presented at the AD/PD™ conference in Copenhagen, showed that patients choose to remain on treatment over a long period and that the disease-slowing treatment effect was sustained for up to four years of treatment Sales of Leqembi exceeded EUR 500 M during Eisai's financial year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 M Events after the end of the period The Swedish NT Council announced that it currently does not recommend the introduction of Leqembi in Swedish healthcare The FDA has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi® Iqlik™ by three months. The application concerns subcutaneous administration of Leqembi as an initiation treatment for early Alzheimer's disease.
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
2026-05-15 12:50:46
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
2026-04-21 06:53:05
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
2026-04-18 09:00:00
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Frequently Asked Questions
-
What is the current Eisai Co., Ltd. (ESALF) stock price?
-
Eisai Co., Ltd.(OTC:ESALF) stock price is $26.18 in the last trading session. During the trading session, ESALF stock reached the peak price of $35.83 while $23.88 was the lowest point it dropped to. The percentage change in ESALF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ESALF stock was $0.
-
ESALF's industry and sector of operation?
-
The OTC listed ESALF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ESALF?
-
Teruyuki Masaka | Vice President and Chief HR Officer, Corporate Communications, Sustainability & General Affairs
Yanhui Feng | Senior Vice President
Shin Kato | Vice President, General Counsel & Chief Compliance Officer
Katsutoshi Ido | Vice President, Chief Scientific Officer & Head of DHBL Discoverry
Lynn D. Kramer FAAN | Vice President & Chief Clinical Officer -
How many employees does ESALF have?
-
Number of ESALF employees currently stands at 10543. ESALF operates from 4-6-10, Koishikawa, Tokyo, TY 112-8088, JP.
-
Link for ESALF official website?
-
Official Website of ESALF is: https://www.eisai.com
-
How do I contact ESALF?
-
ESALF could be contacted at phone #81 3 3817 3700 and can also be accessed through its website. ESALF operates from 4-6-10, Koishikawa, Tokyo, TY 112-8088, JP.
-
How many shares of ESALF are traded daily?
-
The average number of ESALF shares traded daily for last 3 months was 72.
-
What is the market cap of ESALF currently?
-
The market value of ESALF currently stands at $7.39B with its latest stock price at $26.18